Emergent BioSolutions Inc. (EBS) has signed a $174 million deal to provide contract development and manufacturing for AstraZeneca’s (AZN) COVID-19 vaccine candidate, AZD1222.As part of the agreement, Emergent will start this year to produce drug substance at large scale for commercial supply. The contract valid until 2021, follows a $87 million contract in June, which Emergent signed for the development of AstraZeneca’s vaccine candidate. Together the agreements bring AstraZeneca’s commitment to a total of $261 million.AstraZeneca, which is developing AZD1222 together with Oxford University, has in recent weeks signed supply chain agreements for the capacity to produce 2 billion doses …read more
Source:: Yahoo Finance
